No Data
Junshi Biotech\'s 2025 First Quarter Report
JUNSHI BIO (688180.SH) reported a net loss of 0.235 billion yuan in the first quarter.
Glory Exchange, April 25丨JUNSHI BIO (688180.SH) released its quarterly report, achieving total operating income of 0.501 billion yuan in the first quarter of 2025, a year-on-year increase of 31.46%; Net income attributable to shareholders of the parent company was -0.235 billion yuan, a decrease of 48.1529 million yuan compared to the same period last year; EPS is -0.24 yuan.
JUNSHI BIO (01877) announced its first quarter results, with a net loss attributable to parent company of approximately 0.235 billion yuan, narrowing by 17% year-on-year.
JUNSHI BIO (01877) announced its first quarter performance for 2025, with revenue of approximately 0.5 billion yuan, a year-on-year increase of 31....
JUNSHI BIO: OVERSEAS REGULATORY ANNOUNCEMENT - SHANGHAI JUNSHI BIOSCIENCES CO., LTD.* 2025 FIRST QUARTERLY REPORT
JUNSHI BIO (01877) has appointed Wang Yuzhou as the company's securities representative.
JUNSHI BIO (01877) announced that the company will hold the eighth meeting of the fourth Board of Directors on April 25, 2025...
JUNSHI BIO (01877.HK): The new indication application for Trepulimab as a first-line treatment for melanoma has been approved.
Globe News on April 25丨JUNSHI BIO (01877.HK) announced that the company has received a Pharmaceutical Registration Certificate approved by the National Medical Products Administration. The new indication application for the first-line treatment of unresectable or metastatic melanoma with Toripalimab (trade name: Tuoyi) has been approved. This is the twelfth indication for Toripalimab approved in mainland China. The approval of this new indication is primarily based on the data results of the MELATORCH study (NCT03430297). This study is a multicenter, randomized, open-label, positive-controlled Phase III clinical trial, and is.
Further Weakness as Shanghai Junshi Biosciences (HKG:1877) Drops 3.2% This Week, Taking Three-year Losses to 83%
